CLDN18.2在晚期胃癌中的研究进展

Research Progress on CLDN18.2 in Advanced Gastric Cancer

紧密连接蛋白18.2(CLDN18.2)表达于正常胃黏膜上皮细胞,并表达于胃癌、结肠癌、胰腺癌等实体瘤中,是目前消化系统肿瘤治疗的潜在靶点。针对CLDN18.2的靶向治疗主要包括单克隆抗体、嵌合抗原受体T细胞(chimeric antigen receptor T-cell,CAR-T)疗法、双特异性抗体和抗体偶联药物。目前已有多项靶向CLDN18.2的药物进入临床试验,其中以佐妥昔单抗(Zolbetuximab)进展最快。全文就CLDN18.2及其在晚期胃癌中的临床研究进展进行综述。

Tight junction protein CLDN18.2 is expressed in normal gastric mucosal epithelial cells and also in solid tumors such as gastric,colon,and pancreatic cancers,which is a potential therapeutic target for digestive system tumors.Various targeted therapies against CLDN18.2 have been designed,including monoclonal antibody,chimeric antigen receptor T-cell therapy(CAR-T),bispecific antibody,and antibody-drug conjugate.Currently,clinical trials of several CLDN18.2-targeting drugs are ongoing,among which trials of Zolbetuximab have been advanced most.This paper provides a comprehensive review of research progress on CLDN18.2 and its applications in advanced gastric cancer.